Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

528.500
0.000
Volume:303.90K
Turnover:160.36M
Market Cap:126.31B
PE:-274.21
High:537.500
Open:519.000
Low:519.000
Close:528.500
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.51
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.927
ROE:-9.34%
ROA:-5.11%
PB:22.31
PE(LYR):-274.21
PS:52.76

Loading ...

Sichuan Kelun-Biotech Biopharmaceutical Receives NMPA IND Approval for Skb565

Reuters
·
Jul 27

Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-Payload ADC Skb565

THOMSON REUTERS
·
Jul 27

SKB BIO Receives NMPA Approval for Clinical Trial of Novel Dual-Load ADC Drug

Stock News
·
Jul 27

Kelun-Biotech Wins China IND Clearance for Skb565 in Advanced Solid Tumors

Reuters
·
Jul 27

Sichuan Kelun-Biotech Biopharmaceutical Co - Receives Nmpa Ind Approval for Skb565 for Advanced Solid Tumors

THOMSON REUTERS
·
Jul 27

Movement Alert|Kelun-Biotech Rises 3.03% in Regular Trading, Investment Banks Raise Target Prices as Public Funds Trigger Disclosure Threshold

Market Focus
·
Jul 22

Movement Alert|Kelun-Biotech Rises 3.62% at Open, Investment Banks Raise Target Prices Amid Institutional Accumulation Wave

Market Focus
·
Jul 22

Movement Alert|Kelun-Biotech Rises 3.08% in Regular Trading, Multiple Investment Banks Raise Target Prices Amid Institutional Buying Wave

Market Focus
·
Jul 21

JPMorgan Raises Price Target for SKB BIO to HK$648, Maintains Overweight Rating

Deep News
·
Jul 20

Movement Alert|Kelun-Biotech Rises 3.41% in Regular Trading, Multiple Banks Raise Target Price Amid Biotech Sector Rebound

Market Focus
·
Jul 20

Movement Alert|Kelun-Biotech Falls 3.25% in Regular Trading, Post-Clinical-Milestone Profit-Taking Continues Amid Sector-Wide Weakness

Market Focus
·
Jul 17

HBM Holdings's Asthma Drug Candidate Secures China's Approval

MT Newswires Live
·
Jul 16

Goldman Sachs Reiterates Buy Rating on Kelun-Bota Biopharma, Raises Target Price to HK$582.95

Deep News
·
Jul 16

Movement Alert|Kelun-Biotech Falls 3.45% in Regular Trading, Profit-Taking After Prior Session Clinical Data Rally

Market Focus
·
Jul 16

Merck Rises After Partner Kelun-biotech Reports Positive Keytruda Lung Cancer Study

Reuters
·
Jul 15

SKB BIO Secures HK$2.7 Billion Placement to Fund R&D, Total Post-IPO Fundraising Approaches HK$7 Billion

Deep News
·
Jul 15

China NMPA Clears Kelun-biotech, Harbour Biomed Asthma IND for Skb575/hbm7575

Reuters
·
Jul 15

Hbm Holdings - Hbm7575 Co-developed by Harbour Biomed and Kelun-biotech

THOMSON REUTERS
·
Jul 15

Kelun-biotech and Harbour Biomed Announce Nmpa Approval of Ind Application for Skb575/hbm7575 for the Treatment of Asthma

THOMSON REUTERS
·
Jul 15

Kelun-Biotech's Lung Cancer Drug Trial Meets Primary Endpoint

MT Newswires Live
·
Jul 15